by Clinical Neuropsychologist Online | Monday, October 21, 2024 | Dementia
Abstract INTRODUCTION Cerebrospinal fluid (CSF) α-synuclein (α-syn) seed amplification assay (SAA) is a sensitive and specific tool for detecting Lewy body co-pathology in Alzheimer’s disease. METHODS A total of 1637 cross-sectional and 407 longitudinal CSF...
by Clinical Neuropsychologist Online | Monday, October 21, 2024 | Dementia
Abstract INTRODUCTION This study assessed the association of plasma biomarkers of endothelial dysfunction with cognitive performance and decline. METHODS Data from 9414 individuals from eight Dutch cohorts were included (Ø age-range: 57–93 years). Plasma biomarkers...
by Clinical Neuropsychologist Online | Monday, October 21, 2024 | Dementia
Abstract INTRODUCTION The genetic basis of Alzheimer’s disease (AD) in Koreans is poorly understood. METHODS We performed an AD genome-wide association study using whole-genome sequence data from 3540 Koreans (1583 AD cases, 1957 controls) and single-nucleotide...
by Clinical Neuropsychologist Online | Wednesday, October 16, 2024 | Dementia
Abstract INTRODUCTION Our understanding of how fine particulate matter (PM2.5) impacts cognitive functioning is limited. Systemic inflammation processes may play a role in mediating this effect. METHODS This prospective cohort study used data from 66,254 participants...
by Clinical Neuropsychologist Online | Wednesday, October 16, 2024 | Dementia
Abstract INTRODUCTION Blood–brain barrier (BBB) dysfunction occurs in Alzheimer’s disease (AD). Yet, the stage at which it appears along the AD time course and whether it contributes to neurodegeneration remain unclear. METHODS Older adults (61 to 90 years) from...
